Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan Kulkarni (opens original article in a new tab)

Indian pharmaceutical companies are transitioning from generic drug manufacturing to innovation-driven biopharma, but market valuations have not yet reflected this shift. Analysts highlight growing investments in biotechnology, specialty therapies, and global partnerships, with GLP-1 drugs poised to reshape diabetes treatment. The sector's transformation is underway, but investor models remain focused on outdated generic drug pipelines.

• Indian pharma companies are shifting from generics to innovation-driven models with higher margins
• Market valuation still lags behind the sector's transformation toward biotech and specialty therapies
• GLP-1 drugs are expected to replace insulin in diabetes treatment, creating new opportunities